Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib

Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Saglio, Giuseppe, Apperley, Jane F., Arthur, Christopher, Bullorsky, Eduardo, Charbonnier, Aude, Dipersio, John F., Kantarjian, Hagop, Khoury, Hanna Jean, Kim, Dong-Wook, Healey, Diane, Strauss, Lewis and Cortes, Jorge E. 2018. Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib. Blood Cancer Journal 8 (9) , 88. 10.1038/s41408-018-0122-3

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (414kB) | Preview

Abstract

Treatment with a frontline BCR-ABL1 tyrosine kinase inhibitor (TKI; e.g., imatinib, dasatinib, and nilotinib) allows patients with chronic myeloid leukemia (CML) in chronic phase (CP) to achieve a near normal life expectancy1, whereas treatment for CML in accelerated phase (AP) is more problematic. While reports describe outcomes for patients with CML-AP at initial diagnosis2,3, outcomes have been historically worse once CP disease has progressed to AP. Approximately 50% of patients with CML-AP who receive imatinib as initial treatment develop imatinib resistance4 and experience disease progression5. Second-generation TKIs are indicated for patients with CML-CP or advanced CML resistant to/intolerant of prior therapy (including imatinib)6. After initial approval of dasatinib twice a day (BID) for the treatment of patients with CML resistant to/intolerant of imatinib in all stages, this phase 3 CA180-035 study (NCT00123487) was developed to investigate once (QD) or twice (BID) a day dasatinib treatment in patients with CML-AP, CML in blast phase, or Ph+ acute lymphoblastic leukemia resistant to/intolerant of imatinib.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Additional Information:	Open Access This article is licensed under a Creative Commons Attribution 4.0 International License
Publisher:	Springer Nature
ISSN:	2044-5385
Date of First Compliant Deposit:	7 January 2019
Date of Acceptance:	8 September 2018
Last Modified:	05 May 2023 12:44
URI:	https://orca.cardiff.ac.uk/id/eprint/118157

Citation Data

Cited 17 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item